Breast cancer remains one of the most prevalent and deadly cancers among women worldwide, with early detection being critical to improving patient outcomes. Mammograms, the frontline imaging tool for breast cancer screening, have traditionally been interpreted manually or with rudimentary computer assistance, primarily focusing on visible abnormalities. However, emerging deep learning (DL) techniques promise to decode subtler imaging biomarkers—patterns and features within the breast tissue that may signal an increased risk of cancer years before clinical manifestation.

The current study centers on Mirai, a cutting-edge deep learning model trained exclusively on mammographic images to predict breast cancer risk. Mirai harnesses complex patterns that escape conventional radiological assessment, extracting probabilistic risk estimations from raw imaging data. While Mirai has already demonstrated impressive predictive power, the researchers posited that integrating genetic data could elevate this approach. Specifically, they explored the incorporation of polygenic risk scores (PRS), which aggregate the effect of thousands of common genetic variants associated with breast cancer susceptibility.

Polygenic risk scores have emerged as a powerful genomic tool that quantify inherited cancer predisposition across a continuum of risk rather than relying on rare high-penetrance mutations alone. PRS capture immense genetic complexity and have been validated for breast cancer risk stratification in diverse populations. However, PRS alone do not provide spatial or temporal resolution about tissue changes, which imaging biomarkers uniquely offer. The fusion of these two complementary risk layers—image-based phenotypic risk and genotype-based inherited risk—conceptually promises a paradigm shift towards holistic, multi-modal risk prediction.

In this rigorous evaluation, the research team utilized a large, well-characterized cohort with comprehensive mammographic imaging and genotype data. They applied Mirai to mammograms to generate personalized risk estimates, then integrated these with independently derived polygenic risk scores calculated from participants’ genome-wide variant data. The integration was designed to assess additive or synergistic improvements in prediction accuracy, calibrated risk stratification, and clinical applicability.

The results, published in the British Journal of Cancer, confirm that while Mirai’s imaging-only predictions are robust, the addition of polygenic risk scores enhances discriminatory ability modestly but consistently. This finding is critical because even incremental gains in early risk prediction translate to significant clinical impact in terms of screening intervals, preventive interventions, and resource allocation. The combined model showed superior stratification of individuals into meaningful risk categories compared to either modality alone.

A key technical insight underpinning this success lies in the complementary nature of data sources. Mammographic images encode phenotypic manifestations of risk that can result from hormonal, environmental, or aging-related influences, while polygenic risk scores reflect inherited susceptibility embedded within the genome. By applying advanced probabilistic modeling techniques, the researchers effectively merged heterogeneous data to produce a unified risk estimate with enhanced predictive confidence.

Moreover, the study delved into how the integrated model performs across subpopulations, including different age groups, breast density categories, and ancestral backgrounds. Encouragingly, the combined approach maintained its performance robustness, suggesting broad clinical utility. This addresses a persistent challenge in breast cancer risk prediction—ensuring equitable accuracy across population strata commonly underrepresented in genomic and imaging datasets.

The implications of integrating AI-driven imaging biomarkers with polygenic risk extend well beyond risk estimation. The framework sets a precedent for multi-modal precision medicine where imaging, genomics, and potentially other data types like blood biomarkers or lifestyle factors can be cohesively analyzed. This could revolutionize how screening programs are personalized, enabling dynamic adjustment of screening frequency and modality based on evolving composite risk profiles.

Nevertheless, the authors acknowledge limitations and important areas for future investigation. The study cohort, while large, primarily represented populations of European ancestry, necessitating validation in more diverse ethnic groups given variability in genetic architecture. Additionally, the incremental performance boost, though statistically significant, underscores the need for further refinement in fusion algorithms and exploration of additional biomarkers to maximize predictive gains.

The integration of deep learning mammographic models with polygenic risk scores exemplifies a transformative trend in oncology—leveraging the power of AI and genomics to move beyond binary disease classification towards nuanced, individualized risk landscapes. It heralds a future where women can receive personalized breast cancer screening schedules tailored not only to imaging findings but also to their unique genetic risk, enabling earlier interventions that could substantially reduce morbidity and mortality.

This study lays a crucial foundation for clinical translation, emphasizing the potential for integrated multi-modal risk prediction tools to become standard components of breast cancer prevention strategies. As computational and genomic technologies continue to advance, we can expect progressively refined models that incorporate even deeper layers of biological complexity, from tumor microenvironment imaging to epigenetic modifications.

Importantly, this research underscores the need for collaborative efforts bridging radiology, genetics, data science, and clinical oncology to develop, validate, and implement these sophisticated predictive models in real-world healthcare settings. Ensuring interpretability, ease of integration into clinical workflows, and equitable access will be paramount challenges as these tools transition from research to practice.

Ultimately, the combination of imaging biomarkers and polygenic risk scores represents a monumental leap towards personalized oncology. It exemplifies how contemporary medicine harnesses massive data, sophisticated algorithms, and biological insights to tackle one of the most pressing health issues faced by women worldwide. The promise of AI-augmented genomic medicine in breast cancer risk prediction is not just to improve statistics but to transform lives through earlier, wiser, and more individualized care.

As breast cancer prevention enters this new era, the synergy between human biology and machine intelligence will redefine what is possible in early detection and precision intervention. This landmark study by Azam et al. thus serves as both a scientific milestone and a beacon guiding future exploration at the nexus of medical imaging and genomics, sparking renewed hope in the global fight against breast cancer.

Subject of Research: Breast cancer risk prediction using deep learning mammographic models combined with polygenic risk scores.

Article Title: Performance of an image-only deep learning breast cancer risk model with the addition of a polygenic risk score.

Article References:
Azam, S., Lamb, L.R., Eliassen, A.H. et al. Performance of an image-only deep learning breast cancer risk model with the addition of a polygenic risk score. Br J Cancer (2026). https://doi.org/10.1038/s41416-026-03415-z

Image Credits: AI Generated

DOI: 06 April 2026

Aspirin, widely lauded for its cardioprotective properties, has long been under investigation for its potential anti-cancer benefits, especially given its anti-inflammatory and antiplatelet mechanisms. However, earlier studies yielded mixed or inconclusive results regarding its role in reducing cancer incidence or mortality in older adults. The latest analysis digs deeper, employing sophisticated individualized treatment effect modeling to explore how the benefits of low-dose aspirin differ across diverse subgroups of older populations.

The researchers implemented advanced data-processing algorithms and statistical models designed to handle heterogeneity in treatment response. These methods allow for the disaggregation of aggregate trial results to discern the nuanced profiles of patients who might derive significant cancer-preventive benefits from aspirin versus those for whom the risks might outweigh the benefits. Such analytical rigor represents a paradigm shift from traditional clinical trials that often report average treatment effects without accounting for internal variability.

Emerging from a comprehensive meta-analysis of multiple clinical datasets, this study meticulously evaluated parameters such as genetic markers, comorbidities, lifestyle factors, and baseline inflammation levels. Factors like age stratification beyond the typical “older adult” classification, as well as pre-existing medication use and cancer risk profiles, were scrutinized. The granularity of this approach allowed the team to identify specific phenotypes of older adults who respond optimally to aspirin interventions in oncologic prevention.

Biologically, aspirin’s chemopreventive mechanisms are thought to stem from its ability to inhibit cyclooxygenase enzymes (COX-1 and COX-2), subsequently reducing prostaglandin synthesis, which plays a role in tumorigenesis and cancer progression. Nonetheless, individual variability in COX enzyme expression and activity may mediate differential responses, a factor now illuminated in the context of age-associated biological changes. This underscores the necessity to explore biomarkers that predict aspirin sensitivity and respective cancer outcomes.

Another crucial aspect addressed in the analysis pertains to aspirin’s side effect profile, particularly bleeding risk, which escalates with age and can offset potential benefits. Balancing chemopreventive advantages against hemorrhagic complications remains a delicate endeavor. The study’s personalized risk-benefit framework aids clinicians in making nuanced decisions, aligning aspirin therapy with patient-specific hemorrhagic and oncologic risk profiles.

Despite the promising insights, the authors underscore the preliminary nature of these findings and advocate for further investigations. Longitudinal studies with larger stratified cohorts and mechanistic explorations are imperative to validate and extend these observations. Integration of genomic and proteomic data could further enhance the precision of individualized treatment effect predictions.

The impact of this research extends beyond oncology, challenging the broader medical community to rethink preventive pharmacotherapy in geriatric populations through the lens of personalized medicine. The advent of computational data analysis, as harnessed in this study, exemplifies the transformative potential of interdisciplinary approaches combining clinical expertise with data science.

In clinical practice, these insights could recalibrate guidelines, prompting oncologists and primary care physicians to move towards individualized aspirin regimens grounded in comprehensive patient assessments rather than uniform prescriptions. Such shifts promise not only optimized patient outcomes but also reduced incidence of adverse events linked to inappropriate aspirin use.

Equally compelling is how this study enhances our understanding of cancer pathophysiology in older adults, a demographic often underrepresented in clinical research. Addressing this gap is critical given demographic shifts towards aging populations worldwide, which pose growing oncologic healthcare challenges.

As personalized medicine evolves, leveraging such individualized treatment effect analyses will be essential in refining prevention strategies for multifactorial diseases like cancer. This study serves as a clarion call for researchers and clinicians alike to prioritize patient-centered approaches in cancer chemoprevention trials and treatment algorithms.

In summary, the study highlights that low-dose aspirin is not a universally beneficial strategy for cancer prevention in the elderly; rather, its effect is modulated by intricate patient-specific factors demanding thorough evaluation. This landmark research paves the way for more targeted, data-driven prophylactic therapies in oncology and reinforces the critical intersect between aging, pharmacology, and precision health.

For further inquiries or to engage with the corresponding author, Dr. Le Thi Phuong Thao, reach out via email at thao.le@monash.edu. The full study, embargoed but soon accessible through designated media channels, promises to ignite essential discourse in medical and scientific communities around the optimization of cancer preventive care in older populations.

Subject of Research: The individualized effects of low-dose aspirin on cancer prevention in older adults

Article Title: Not specified

News Publication Date: Not specified

Web References: Not provided

References: (doi:10.1001/jamaoncol.2025.3593)

Image Credits: Not provided

Keywords: Cancer, Analgesics, Medications, Older adults, Data analysis, Disease prevention, Medical treatments, Oncology